Skip to main content
SpringerLink
Log in

Virussicherheit von Gerinnungspräparaten

  • Conference paper
Fachübergreifende Aspekte der Hämostaseologie

  • 24 Accesses

Zusammenfassung

Die meisten durch Bluttransfusionen oder durch Gabe von Plasmaprodukten verursachten Todesfalle sind auch heute noch auf die Übertragung infektiöser Agenzien zurückzuführen [17, 40, 87, 131]. Infektiöse Komplikationen nach Gabe von Blutprodukten stellen somit ein größeres Transfusionsrisiko dar, als alle anderen Transfusionsrisiken zusammengenommen, Blutgruppenverwechslungen und antikörperbedingte Transfusionszwischenfalle eingeschlossen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Afting EG (1993) Entwicklung neuer Arzneimittel durch Biotechnologie. Die gelben Hefte 33: 1–12

    Google Scholar 

  2. Alter HJ, Creagan RP, Morel PA (1988) Photochemical decontamination of blood components containing hepatitis B and non-A, non-B virus. Lancet 2: 1446–1450

    Article  PubMed  CAS  Google Scholar 

  3. Andreu G, Boccaccio C, Lecrubier C (1990) UV irradiation of platelet concentrates: feasibility in transfusion practice. Transfusion 30: 401–406

    Article  PubMed  CAS  Google Scholar 

  4. Aronson DL (1990) The development of the technology and capacity for the production of factor VIII for the treatment of hemophilia. Transfusion 30: 748–758

    Article  PubMed  CAS  Google Scholar 

  5. Arrighi S, Pacenti L, Borri MG (1993) Factor VIII: C concentrate virus inactivated: Progress in purification by using classic chromatographic methods. Vox Sang 64: 13–18

    Article  PubMed  CAS  Google Scholar 

  6. Auerswald G, Fengler A, Holfeld E et al. (1990) Virus safety of pasteurized factor IX concentrate. Biomedical Progress 3: 460–461

    Google Scholar 

  7. Azzi A, Ciappi S, Mannucci PM (1992) Human parvovirus B19 infection in hemophiliacs first infused with 2 high — purity, virally attenuated factor VIII concentrates. Am J Hematol 39: 228–230

    Article  PubMed  CAS  Google Scholar 

  8. Berntorp E, Nilssin IM (1989) Use of a high purity factor VIII concentrate in von Willebrand’s disease. Vox Sang 56: 212–217

    Article  PubMed  CAS  Google Scholar 

  9. Björkander J, Cunningham-Rundles C, Lundin P (1988) iv Immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia. Am J Med 84: 107–111

    Article  PubMed  Google Scholar 

  10. Blum HE, Weizaecker Fv, Walter E (1993) Gentechnologie: medizinische Bedeutung. DMW 118: 629–633

    Article  CAS  Google Scholar 

  11. Boedeker BGD (1992) The manufacturing of the recombinant factor VIII, kongenate. Transfusion Med Rev 6: 256–260

    Article  CAS  Google Scholar 

  12. Bradley DW (1992) Virology and molecular biology and serology of hepatitis C virus. Transfusion Med Rev 6: 93–102

    Article  CAS  Google Scholar 

  13. Brackmann HH, Egli H (1988) Acute hepatitis B infection after treatment with heat inactivated factor VIII concentrate. Lancet ii: 967

    Article  Google Scholar 

  14. Bradley D, Maynard J, Popper H (1983) Post transfusion non-A, non-B hepatitis. J Infect Dis 148: 254–265

    Article  PubMed  CAS  Google Scholar 

  15. Brand A, Rood JJ van, Claas FHJ (1989) UV-irradiated platelets: ready to use? Transfusion 29: 377–378

    Article  PubMed  CAS  Google Scholar 

  16. Braunstein AH, Obermann HA (1984) Transfusion of plasma components. Transfusion 24: 281–286

    Article  PubMed  CAS  Google Scholar 

  17. Brennan MT, Barbara JAJ (1993) Transfusion transmitted disease. Curr Opin Hemat 1: 320–329

    Google Scholar 

  18. Brettler DB, Levine PH (1989) Factor concentrates for treatment of hemophilia: which one to choose? Blood 73: 2067–2073

    PubMed  CAS  Google Scholar 

  19. O’Brien JM, Sieber F (1989) Mutagenicity of merocyanine 540 — mediated photo-sensitization. Exp Hematol 17: 166–170

    PubMed  Google Scholar 

  20. Bundesgesundheitsamt (1993) Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln. Abwehr von Arzneimittelrisiken. Bundesanzeiger 61: 3043

    Google Scholar 

  21. Chernoff AI, Klein HG, Sherman LA (1989) Research opportunities in transfusion medicine. Transfusion 29: 711–742

    Article  Google Scholar 

  22. Clemens R (1987) Virus safety of a pasteurized AT III concentrate. Drug Res 37: 759–762

    CAS  Google Scholar 

  23. Clifton CE (1931) Photodynamic action of certain dyes on the inactivation of staphylococcus bacteriophage. Proc Soc Exp Biol Med 28: 745–746

    CAS  Google Scholar 

  24. Cole M, Stromberg R, Friedman L (1989) Photochemical inactivation of virus in red cells. Transfusion 29:145 Abstr

    Google Scholar 

  25. Colombo M, Carnelli V, Gazengel C (1985) Transmission of Non-A and Non-B hepatitis by heat treated factor VIII concentrate. Lancet ii: 1–4

    Google Scholar 

  26. Colombo M, Morfini M, Mannuccii PM (1990) Virus inactivation in clotting factor concentrates. Transf Sci 11: 43–49

    Article  Google Scholar 

  27. Cornetta K (1992) Safety aspects of gene therapy. Brit J Haematol 80: 421–426

    Article  CAS  Google Scholar 

  28. Deeg HJ (1989) Transfusions with a tan. Transfusion 29: 450–454

    Article  PubMed  CAS  Google Scholar 

  29. Dietrich SL, Mosley JW, Lusher JM (1990) Transmission of HIV-1 by dry heated clotting factor concentrates. Vox Sang 59: 129–135

    Article  PubMed  CAS  Google Scholar 

  30. Dupont WD (1990) Power and sample size calculations. Controlled Clinical Trials 11: 116–129

    Article  PubMed  CAS  Google Scholar 

  31. Eckstein R (1988) Bluttransfusion und Infektionskrankheiten. In: Fortbildungsprogramm Serologie/Immunologie 1988, Biotest, Berlin 5.5. 1988, S. 1–47

    Google Scholar 

  32. Einarsson M, Perenius L, Cort S (1989) Heat inactivation of human immunodeficiency virus in solutions of antithrombin III. Transfusion 29: 148–152

    Article  PubMed  CAS  Google Scholar 

  33. Emmons RW (1988) Ecology of Colorado tick fever. Ann Rev Microbiol 42: 49–64

    Article  CAS  Google Scholar 

  34. Esmonde TFG, Will RG, Matthews WB (1993) Creutzfeldt-Jakob disease and blood transfusion. Lancet 341: 205–207

    Article  PubMed  CAS  Google Scholar 

  35. Farber EM, Abel EA, Cox AJ (1983) Long term risks of psoralen and UV therapy for psoriasis. Arch Dermatol 119: 426–431

    Article  PubMed  CAS  Google Scholar 

  36. Fields BN (1992) Hepatitis A Virus. In: Fields BN, Knipe DM (eds) Virology, Vol 1. Raven Press, New York, pp 631–667

    Google Scholar 

  37. Fratantoni JC, Prodouz KN, Horowitz MS (1990) Viral inactivation of blood products. Transfusion 30: 480–481

    Article  PubMed  CAS  Google Scholar 

  38. Fricke WA, Lamb MA (1993) Viral safety of clotting factor concentrates. Sem Haemost Thromb 19: 54–61

    Article  CAS  Google Scholar 

  39. Gerritzen A (1992) Acute hepatitis in hemophiliacs. Lancet 340: 1231–1232

    Article  PubMed  CAS  Google Scholar 

  40. Goldmann M (1991) Blood product associated bacterial sepsis. Transf Med Rev 5: 73–83

    Article  Google Scholar 

  41. Gomberts ED, Biasi R, Vreker R (1992) The impact of clotting factor concentrates on the immune system. Transfusion Med Rev 6: 44–54

    Article  Google Scholar 

  42. Gomberts E, Lundblad R, Adamson R (1992) The manufacturing process of recombinant factor VIII. Transfusion Med Rev 6: 247–251

    Article  Google Scholar 

  43. Green MS, Tsur S, Slepon R (1992) Sociodemographic factors and the declining prevalence of antihepatitis A antibodies in young adults in Israel. Int J Epidemiol 21: 136–141

    Article  PubMed  CAS  Google Scholar 

  44. Gregersen JP, Hilfenhaus J, Lemp JF (1989) Heat inactivation of HIV-2. J Biol Standard 17: 377–379

    Article  CAS  Google Scholar 

  45. Growe GH, Poon M, Scarth I (1992) International Symposium on recombinant factor VIII. Transfusion Med Rev 6: 137–145

    Article  CAS  Google Scholar 

  46. Guertler L, Schramm W (1993) Infektionsgefahrdung durch Blut oder Blutbestandteile. DMW 118: 520–522

    Article  Google Scholar 

  47. Harris JW (1992) Parvovirus B19 for the hematologist. Am J Hematol 39: 119–130

    Article  PubMed  CAS  Google Scholar 

  48. Hiemstra H, Tersmette M, Vos AHV (1991) Inactivation of HIV by gamma radiation and its effect on plasma and coagulation factors. Transfusion 31: 32–39

    Article  PubMed  CAS  Google Scholar 

  49. Horowitz B (1989) Investigations into the application of Tri(n-butyl)phosphate/detergent mixtures to blood derivatives. Curr Stud Hematol Blood Transf 56: 83–96

    Google Scholar 

  50. Horowitz B, Wiebe M, Lippin A (1985) Inactivation of viruses in labile blood derivatives. Transfusion 25: 516–527

    Article  PubMed  CAS  Google Scholar 

  51. Horowitz B, Piet MP J, Prionce Am (1988) Inactivation of lipid enveloped viruses in labile blood derivatives by unsaturated fatty acids. Vox Sang 54: 14–20

    Article  PubMed  CAS  Google Scholar 

  52. Horowitz MS, Horowitz B, Hilgartner MW (1988) Virus safety of S/D treated antihemophilic factor concentrate. Lancet ii: 186–188

    Google Scholar 

  53. Horowitz B, Williams B, Rywkin S (1991) Inactivation of viruses in blood with aluminium phthalocyanine derivatives. Transfusion 31: 102–108

    Article  PubMed  CAS  Google Scholar 

  54. Hudson JB, Towers GN (1988) Antiviral properties of photosensitizers. Photochem Photobiol 48: 289–296

    Article  PubMed  CAS  Google Scholar 

  55. Imbach P, Perret BA, Babington R et al. (1991) Safety of intravenous immunoglobulin praeparations. Vox Sang 61: 240–243

    Article  PubMed  CAS  Google Scholar 

  56. Isaac BM (1992) The past and the future: recombinant factor VIII and the consumer. Transfusion Med Rev 6: 280–283

    Article  CAS  Google Scholar 

  57. Jilg W (1991) Aktive und passive Prävention der Virushepatitiden. Internist 32: 249–255

    PubMed  CAS  Google Scholar 

  58. Johnson BH, Johnson MA, Moore MA (1977) Psoralen — DNA photoreaction. Science 197: 906–908

    Article  PubMed  Google Scholar 

  59. Katzenelson E, Kletter B, Shuval HI (1974) Inactivation kinetics of viruses and bacteria in water by use of ozone. J Am Water Works Ass 66: 725–729

    CAS  Google Scholar 

  60. Kaufmann RJ (1992) Expression and structure — function properties of recombinant factor VIII. Transfusion Med Rev 6: 235–246

    Article  Google Scholar 

  61. Kim HC, McMillan CW, White GC, Saidi P (1992) Purified factor IX using monoclonal immunoaffinity techniques. Blood 79: 568–575

    PubMed  CAS  Google Scholar 

  62. Kitchen AD, Mann CF, Harrison JF (1989) Effect of gamma irradiation on the human immundeficieney virus and human coagulation proteins. Vox Sang 56: 223–229

    Article  PubMed  CAS  Google Scholar 

  63. Kiyosawa K, Sodeyama T, Alter HJ (1990) Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma. Hepatology 12: 671–675

    Article  PubMed  CAS  Google Scholar 

  64. Kleim JP, Bailly E, Schneweis KE, Brackmann HH (1990) Acute HIV-1 infection in patients with hemophilia B treated with ß-propiolactone — UV — inactivated clotting factor. Thromb Hemostas 64: 336–337

    CAS  Google Scholar 

  65. Kreuz W, Auerswald G (1992) Prevention of hepatitis C Virus infection in children with hemophilia A and B and von Willebrand’s disease. Thromb Haemostas 67: 184

    CAS  Google Scholar 

  66. Kreuz W, Klarmann D, Auerswald G (1993) Absence of hepatitis A after treatment with pasteurized factor VIII concentrates in children with hemophilia A and von Willebrand disease. Lancet 341: 446

    Article  PubMed  CAS  Google Scholar 

  67. Kurth R (1993) Infektionskrankheiten im Wandel. Die gelben Hefte 33: 13–18

    Google Scholar 

  68. Lane RJM, Dick JPR, Belleroche J (1991) Glycine and neurodegenerative disease. Lancet 337: 732–733

    Article  PubMed  CAS  Google Scholar 

  69. Lane RS (1983) Non-A, Non-B hepatitis from iv immunoglobulins. Lancet ii: 974–975

    Article  Google Scholar 

  70. Lever AML, Webszter ADB, Brown D (1994) Non-A, Non-B hepatitis occuring in a gammaglobulinemic patients after iv immunoglobulin. Lancet ii: 1062–1064

    Google Scholar 

  71. Liemntani SA, Roth D, Furie BC (1993) Recombinant blood clotting factors for hemophilia therapy. Sem Thromb Haemost 19: 62–72

    Article  Google Scholar 

  72. Lin L, Wiesehahn GP, Morel PA (1989) Use of 8-methoxypsoralen and long wavelength uv radiation for decontamination of platelet concentrates. Blood 74: 517–529

    PubMed  CAS  Google Scholar 

  73. Lusher JM, Salzman PM (1990) Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIII C concentrates. Sem Hematol 27: 1–7

    CAS  Google Scholar 

  74. Lusher JM, Arkin S, Abildgaard CF (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. NEJM 328: 453–459

    Article  PubMed  CAS  Google Scholar 

  75. Lytle CD, Carney PG, Feiten RP (1989) Inactivation and mutagenesis of herpes virus by photodynamic treatment with therapeutic dyes. Photoichem Photobiol 50: 367–371

    Article  CAS  Google Scholar 

  76. Majeed FA, Stuard JM, Cartwright KAV, Watson BE (1992) An outbreak of hepatitis A in gloucester, UK. Brit J Haematol 109: 167–173

    CAS  Google Scholar 

  77. Mannucci PM (1985) Anti LAV and Concentrate Consumption in Italian Hemophiliacs. Thromb Hemost 54: 556

    CAS  Google Scholar 

  78. Mannucci PM (1992) Outbreak of hepatitis A among Italian patients with hemophilia. Lancet 339: 819

    Article  PubMed  CAS  Google Scholar 

  79. Mannucci PM (1993) Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang 64: 197–203

    Article  PubMed  CAS  Google Scholar 

  80. Mannucci PM, Colombo M (1988) Virucidal treatment of clotting factor concentrates. Lancet i: 782–785

    Article  Google Scholar 

  81. Mannucci PM, Zanetti AR, Colombo M (1988) Prospective study of hepatitis after factor VIII concentrate exposed to hot vapour. Brit J Hematol 68: 427–430

    Article  CAS  Google Scholar 

  82. Mannucci PM, Colombo M (1989) Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. Thromb Haemostas 61: 532–534

    CAS  Google Scholar 

  83. Mannucci PM, Zanetti AR, Colombo M (1990) Antibody to hepatitis C virus after a vapour heated factor VIII concentrate. Thromb Haemostas 64: 232–234

    CAS  Google Scholar 

  84. Mannucci PM, Schimpf K, Aledort LM, Rivard GE (1992) Low risk of viral infection after administration of vapor heated factor VIII concentrate. Transfusion 32: 134–138

    Article  PubMed  CAS  Google Scholar 

  85. Matthews JL, Newman JT, Songandares-Bernal F (1988) Photodynamic therapy of viral contaminants with potential for blood banking applications. Transfusion 28: 81–83

    Article  PubMed  CAS  Google Scholar 

  86. McCullough J (1992) A new generation of blood components. Transfusion 32: 299–301

    Article  PubMed  CAS  Google Scholar 

  87. McDonald M (1992) Primary and secondary ethical issues arising from the introduction of recombinant factor VIII. Transfusion Med Rev 6: 271–276

    Article  CAS  Google Scholar 

  88. Mollison PL, Engelfriet CP, Conreras M (1987) Blood transfusion in clinical Medicine. Blackwell Scientific Publications, Oxford

    Google Scholar 

  89. Morey AL, Nicolini U, Welch CR (1991) Parvovirus B19 infection and transient fetal hydrops. Lancet 337: 496

    Article  PubMed  CAS  Google Scholar 

  90. Moroff G, Benade LE, Dabey M (1989) Use of photochemical procedures to in-activate viruses in platelet suspensions. Transfusion 29:15 Abst.

    Google Scholar 

  91. Neyndorff HC, Bartel DL, Tufaro F (1990) Development of a model to demonstrate photosensitizer mediated viral inactivation in blood. Transfusion 30: 485–490

    Article  PubMed  CAS  Google Scholar 

  92. Nilsson IM, Berntrorp E, Ljung R (1990) Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate. Lancet 335: 1531–1532

    PubMed  Google Scholar 

  93. Normann A, Graff J, Gerritzen A (1992) Detection of hepatitis A virus DNA in commercially available factor VIII preparations. Lancet 340: 1232–1233

    Article  PubMed  CAS  Google Scholar 

  94. Ochs HD, Fischer SH, Virant FS (1985) Non-A, Non-B hepatitis and iv immunoglobulin. Lancet i: 404–405

    Article  Google Scholar 

  95. Oshiro LS, Dondero DV, Emmous RW (1978) The development of Colorado tick fever virus within cells of the hematopoetic system. J Gen Virol 39: 73–79

    Article  PubMed  CAS  Google Scholar 

  96. Peerlink K, Vermylen J (1993) Acute hepatitis A in patients with hemophilia. Lancet 341: 179

    Article  Google Scholar 

  97. Perdrau JR, Todd C (1933) The photodynamic action of methylene blue on certain viruses. Proc Roy Soc B 112: 288–298

    Article  CAS  Google Scholar 

  98. Piet MP J, Chin S, Prince AM (1990) The use of TNBP detergent mixtures to inactivate hepatitis viruses and HIV in plasma. Transfusion 30: 591–598

    Article  PubMed  CAS  Google Scholar 

  99. Pistello M, Ceccherini NL, Cecconi N et al. (1993) Hepatitis C virus seroprevalence in Italian hemophiliacs injected with virus inactivated concentrates: 5 year followup and correlation with antibodies to other viruses. J Med Virol 33: 43–46

    Article  Google Scholar 

  100. Piszkiewicz D, Sun CS, Tondreau SC (1989) Inactivation and removal of human immundeficiency virus in monoclonal purified antihemophilic factor. Thromb Res 55: 627–634

    Article  PubMed  CAS  Google Scholar 

  101. Piszkiewicz D, Tondreau SC (1990) Inactivation of HIV-2 by solvent/detergent treatment. Transfusion 30: 192

    Article  PubMed  CAS  Google Scholar 

  102. Pollmann H, Binder M, Rockicka-Milewska R (1993) Virus safety results of a TNBP/Tween 80 — treated factor VIII — or IX concentrate in haemophilia treatment (PUP’s study). 37th Ann Meeting GTH, Bad Gasstein 1993

    Google Scholar 

  103. Preiksaitis JK (1991) Indications for the use of cytomegalovirus — seronegative blood products. Transf Med Rev 5: 1–17

    Article  CAS  Google Scholar 

  104. Preiss DU, Eberspächer B, Abdullah D, Rosner I (1991) Safety of vapour heated prothombin complex concentrate (PCC) Prothrombinplex S-TIM 4. Thromb Res 63: 651–659

    Article  PubMed  CAS  Google Scholar 

  105. Preiss D, Abdullah D, Eberspaecher B, Wilhelm K (1992) Safety of virusinactivated Antithrombin-III concentrate. Thromb Res 65: 677–686

    Article  PubMed  CAS  Google Scholar 

  106. Prince AM, Horowitz B, Horowitz MS (1987) The development of virus free labile blood derivatives. Eur J Epidemiol 3: 103–118

    Article  PubMed  CAS  Google Scholar 

  107. Prodouz KN, Fratantoni JC, Boone EJ (1987) Use of laser — uv inactivation of virus in blood products. Blood 70: 589–592

    PubMed  CAS  Google Scholar 

  108. Prodouz KN, Fratantoni JC (1988) Inactivation of virus in blood products. Transfusion 28: 2–3

    Article  PubMed  CAS  Google Scholar 

  109. Roussel RH, Budinger MD, Pirofsky B (1991) Prospective study on the hepatitis safety of iv Immunoglobulin, pH 4.25. Vox Sang 60: 65–68

    Article  Google Scholar 

  110. Review (1988) Ways to reduce the risk of transmission of viral infections by plasma and plasma products. Vox Sang 54: 228–245

    Article  Google Scholar 

  111. Rubinstein AI, Rubinstein DB (1989) Thermal inactivation by sequential dry-heat treatments at sterilizing temperatures of factor VIII and factor IX concentrates to produce sterile concentrates. Vox Sang 57: 272

    Article  PubMed  CAS  Google Scholar 

  112. Scarraggi FA, Perrici A, Petronelli M et al. (1992) Prevalence of serum IgG antibodies against hepatitis A virus in Italian haemophiliacs. Lancet 339: 1486–1487

    Article  Google Scholar 

  113. Schimpf K, Mannucci PM, Kreutz W (1987) Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions. NEJM 316: 918–922

    Article  PubMed  CAS  Google Scholar 

  114. Seyfert UT, Hauck W, Wenzel E (1992) Verfahren zur Inaktivierung von Viren in Plasma und Plasmaderivaten. In: Hellstern P, Maurer C (Hrsg) Neue Entwicklungen in der Transfusionsmedizin. Springer, Berlin Heidelberg New York Tokyo, S. 19–34

    Chapter  Google Scholar 

  115. Sieber F, Spivak JL, Sutcliffe AM (1984) Selective killing of leukemic cells by merocyanine 540 mediated photosensitization. Proc Natl Acad Sci 81: 7584–7587

    Article  PubMed  CAS  Google Scholar 

  116. Sieber F (1987) Yearly review: merocyanine 540. Photochem Photobiol 46: 1035–1042

    Article  PubMed  CAS  Google Scholar 

  117. Sieber F, Krueger GJ, O’Brien JM (1989) Inactivation of Friend erythroleukemia virus and Friend virus -transformed cells by merocyanin 540 mediated photosensitization. Blood 73: 345–350

    PubMed  CAS  Google Scholar 

  118. Singer CRJ, Azim T, Sattentau Q (1988) Preliminary evaluation of phthalocyanine photosensitization for inactivation of viral pathogens in blood products. Br J Hematol 69:111- Abstr.

    Google Scholar 

  119. Smith K (1992) Factor IX concentrates. Transfusion Med Rev 6: 124–136

    Article  CAS  Google Scholar 

  120. Snipes W, Person S, Keller G (1977) Inactivation of lipid containing viruses by long chain alcohols. Antimicrob Agents Chemoth 11: 98–104

    CAS  Google Scholar 

  121. Snyder E, Beardsley D, Smith B (1989) Storage of platelet concentrates after UV irradiation. Blood 74:179 - Abstr.

    Google Scholar 

  122. Stephan W (1988) Virusinaktivierung von Blutprodukten. In: Maass G (Hrsg) Virussicherheit von Blut, Plasma und Plasmaprodukten. Springer, Berlin Heidelberg New York Tokyo, S. 53–61

    Google Scholar 

  123. Stirling D, Ludlam CA (1993) Therapeutical concentrates for the treatment of congenital deficiencies of factor VII, XI and XIII. Sem Thromb Haemost 19: 48–53

    Article  CAS  Google Scholar 

  124. Stuard JM, Majjeed FA, Begg NT (1992) Salivary antibody testing in a school outbreak of hepatitis A. Brit J Haematol 109: 161–166

    Google Scholar 

  125. Temperly IJ (1992) Clotting factors and hepatitis A. Lancet 340: 1466

    Article  Google Scholar 

  126. Thoma KB, Mcgrath KM, Taylor M (1988) Effect of virucidal heat treatment on proteins in human factor VIII concentrates. Transfusion 28: 8–13

    Article  Google Scholar 

  127. Thompson A (1993) Factor IX concentrates for clinical use. Sem Thromb Haemost 19: 25–36

    Article  CAS  Google Scholar 

  128. Uemara Y, Yokoyama K, Nishida M, Suyama T (1989) Immunoglobulin preparations: safe from virus transmission? Vox Sang 57: 1–3

    Article  Google Scholar 

  129. Van der Zee J, Tijssen CK, Dubbelman TMAR (1987) The influence of ozone on human red blood cells. Biochem Biophys Acta 924: 111–118

    Article  PubMed  Google Scholar 

  130. Vaughn JM, Chen YS, Lindburg K (1987) Inactivation of human and simian rotaviruses by ozone. Appl Environ Microbiol 53: 2218–2221

    PubMed  CAS  Google Scholar 

  131. Wagner KF, Mayers DL, Linette GP (1989) Effect of ozone on HIV in experimentally infected blood. CDC Aids Weekly Jan 30: 17

    Google Scholar 

  132. Wagner SJ, Friedman LI, Dodd RY (1991) Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma. Transfusion Medicine Reviews 5: 18–32

    Article  PubMed  CAS  Google Scholar 

  133. Weiland O, Mattson L, Glaumann H (1986) Non-A, Non-B hepatitis after iv gammaglobulin. Lancet i: 975–977

    Google Scholar 

  134. Williams B, Horowitz B, Geacintov N (1988) Inactivation of viruses in cellular blood products. Blood 72:287 - Abst.

    Google Scholar 

  135. Williams PE, Yap PL, Gillon J (1989) Transmission of Non-A, Non-B Hepatitis by pH 4 treated iv Immunoglobulin. Vox Sang 57: 15–18

    Article  PubMed  CAS  Google Scholar 

  136. Winkelman L, Owen NE, Evans DR (1989) Severely heated therapeutic factor VIII concentrate of high specific activity. Vox Sang 57: 97–103

    Article  PubMed  CAS  Google Scholar 

  137. Winslow RM (1993) Indications for and alternatives to homologous transfusion. Curr Opin Hematol 1: 337–341

    Google Scholar 

  138. Yei S, Yu MW, Tankersley DL (1992) Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion 32: 824–8828

    Article  PubMed  CAS  Google Scholar 

  139. Zuck TF (1987) Greetings — a final look back with comments about a policy of a zero-risk blood supply. Transfusion 27: 447–448

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. U. T. Seyfert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Kleinschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Wenzel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Anaesthesiologie, Universität Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland

    E. Martin

  2. Innere Medizin I Universitätsklinik, Universität Heidelberg, Bergheimer Straße 58, 69115, Heidelberg, Deutschland

    P. P. Nawroth

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Seyfert, U.T., Kleinschmidt, S., Wenzel, E. (1994). Virussicherheit von Gerinnungspräparaten. In: Martin, E., Nawroth, P.P. (eds) Fachübergreifende Aspekte der Hämostaseologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93561-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93561-9_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-58054-6

  • Online ISBN: 978-3-642-93561-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation